ANZUP 2023 | CLIMATE: miR-371a-3p as a biomarker in post-orchiectomy testicular cancer

Ciara Conduit, FRACP, MBBS, PGCert MEd, Peter MacCallum Cancer Centre, Melbourne, Australia, comments on updates from the CLIMATE trial (ACTRN12622000247774), which assessed the clinical utility of miR-371a-3p as a marker of residual disease in testicular cancer following orchiectomy. Having a post-operative biomarker will enable patients who test negative for minimal residual disease (MRD) to be spared treatment. Patients with seminoma and non-seminoma testicular cancer were recruited and the trial is currently ongoing. This interview took place at the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group annual scientific meeting in Melbourne, Australia.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.